DNL343 Falls Short of Primary End Point in Phase 2/3 HEALEY-ALS Platform Trial

Published Date: 09 Jan 2025

Over a 24-week period, DNL343 failed to distinguish itself from placebo on the primary end point of ALSFRS-R, as well as on other secondary end points of muscle strength and respiratory function.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Study reveals increase in late-stage breast cancer diagnoses in US

5.

Prostate cancer Q&A: Improving detection and reducing overtreatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot